A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain

Sponsor: Memorial Sloan Kettering Cancer Center

Sponsor score: 60
Inactive

ClinicalTrials ID:NCT05419076

Patient View

This study evaluates the effectiveness of SRS in treating brain metastases from SCLC. Eligible participants are adults with up to 10 brain metastases, a KPS of 60-100, and no prior brain radiotherapy. Interventions include MSK standard SRS and cerebrospinal fluid collection via lumbar puncture. Exclusions include inability to undergo MRI and confirmed leptomeningeal disease.

Patient Parameters

Program Overview

The purpose of the study is to see if stereotactic radiosurgery/SRS is an effective treatment for people with a new diagnosis of brain metastases from small cell lung cancer/SCLC.

Eligibility Criteria

Inclusion Criteria

  • Histologic diagnosis of small cell lung cancer
  • Radiographic diagnosis of up to 10 brain metastases on contrast-enhanced MRI
  • Age 18 and above
  • Performance status KPS 60-100/ECOG 0-2
  • Female patients must be of non-reproductive potential or have a negative serum pregnancy test at the time of enrollment
  • The patient or legally authorized representative is able to provide informed consent

Exclusion Criteria

  • Unable to undergo contrast-enhanced MRI brain or spine
  • Leptomeningeal disease confirmed on lumbar puncture, MRI brain, or MRI spine
  • Pregnant or lactating women
  • Prior brain-directed radiotherapy
  • Uncontrolled systemic disease without reasonable systemic therapy options felt likely to result in death as observed on CT or PET/CT imaging, no more than 3 months before study enrollment

Get This Program In Your Inbox

You can sign up and apply your patients for this program.